Search

Your search keyword '"ISHIDA M"' showing total 5,390 results
Start Over Author "ISHIDA M"
5,390 results on '"ISHIDA M"'

1. Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Author

Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, and Koga N

Subjects
calcitonin gene-related peptide, episodic migraine, fremanezumab, japanese, Medicine (General), R5-920
Abstract

Kazumasa Saigoh,1 Takao Takeshima,2 Masami Nakai,3 Yoshiyuki Shibasaki,4 Miki Ishida,5 Xiaoping Ning,6 Steve Barash,6 Yuki Isogai,4 Nobuyuki Koga7 1Department of Neurology, Kindai University School of Medicine, Osaka, Japan; 2Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan; 3Medical Affairs, Otsuka Pharmaceutical Co, Ltd, Osaka, Japan; 4Medical Affairs, Otsuka Pharmaceutical Co, Ltd, Tokyo, Japan; 5Headquarters of Clinical Development, Otsuka Pharmaceutical Co, Ltd, Osaka, Japan; 6Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA, USA; 7Medical Affairs, Otsuka Pharmaceutical Co, Ltd, Tokushima, JapanCorrespondence: Masami Nakai, Medical Affairs, Otsuka Pharmaceutical Co., Ltd, 3-2-27 Otedori, Chuo-ku, Osaka, 540-0021, Japan, Tel +81-80-9026-3806, Email nakai.masami@otsuka.jpPurpose: The monoclonal antibody fremanezumab has been shown effective and well tolerated in numerous Phase 2 and Phase 3 trials. This subgroup analysis of the international HALO episodic migraine (EM; [NCT02629861]) trial and a similarly designed phase 2b/3 trial in Japanese and Korean patients (NCT03303092) sought to evaluate the efficacy and safety of fremanezumab in Japanese patients with EM.Patients and Methods: In both trials, eligible patients were randomly assigned at baseline to receive subcutaneous monthly fremanezumab, quarterly fremanezumab, or placebo in a 1:1:1 ratio. The primary endpoint was the mean change from baseline in the monthly (28-day) average number of migraine days during the 12-week period after the first dose of fremanezumab or placebo. Secondary endpoints assessed other aspects of efficacy, including disability and medication use.Results: A total of 301 patients in the Japanese and Korean phase 2b/3 trial and 75 patients in the HALO EM trial were Japanese with baseline and treatment characteristics similar between treatment groups. According to ANCOVA analysis of the primary endpoint, both fremanezumab quarterly and monthly led to greater reductions in the monthly (28-day) average number of migraine days than placebo. This was supported by MMRM analysis of the primary endpoint over the initial 4 weeks, highlighting the rapid onset of action of fremanezumab. Results of secondary endpoint analysis supported the primary endpoint analyses. Fremanezumab was well tolerated with no new safety signals seen in this population of Japanese patients.Conclusion: Fremanezumab appears to be an effective and well-tolerated preventive medication for Japanese patients with EM.Keywords: calcitonin gene-related peptide, episodic migraine, fremanezumab, Japanese

Published
2023

2. Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

Author

Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, and Koga N

Subjects
calcitonin gene-related peptide, chronic migraine, fremanezumab, japanese, Medicine (General), R5-920
Abstract

Kazumasa Saigoh,1 Takao Takeshima,2 Masami Nakai,3 Yoshiyuki Shibasaki,4 Miki Ishida,5 Xiaoping Ning,6 Steve Barash,6 Yuki Isogai,4 Nobuyuki Koga7 1Department of Neurology, Kindai University School of Medicine, Osaka, Japan; 2Headache Center, Department of Neurology, Tominaga Hospital, Osaka, Japan; 3Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan; 4Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan; 5Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan; 6Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA; 7Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, JapanCorrespondence: Masami Nakai, Medical Affairs, Otsuka Pharmaceutical Co., Ltd., 3-2-27 Otedori, Chuo-ku, Osaka, 540-0021, Japan, Tel +81-80-9026-3806, Email nakai.masami@otsuka.jpPurpose: Fremanezumab monoclonal antibody therapy has demonstrated efficacy for chronic migraine (CM) with rapid onset and good tolerability. This subgroup analysis of two clinical trials (Japanese and Korean CM Phase 2b/3 [NCT03303079] and HALO CM Phase 3 [NCT02621931]) aimed to evaluate the efficacy and safety of fremanezumab in Japanese patients.Patients and Methods: Both trials randomly assigned eligible patients at baseline (1:1:1 ratio) to subcutaneous monthly fremanezumab, quarterly fremanezumab, or placebo at 4-week intervals. The primary endpoint was the mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12-week period after the first dose of study medication (analyzed by ANCOVA over 12 weeks and MMRM over initial 4 weeks). Secondary endpoints examined other aspects of efficacy, including medication use and disability.Results: A total of 479 and 109 patients were Japanese in the Japanese and Korean CM Phase 2b/3 and HALO CM trials, respectively. Baseline and treatment characteristics were generally similar between treatment groups for both trials. Results of subgroup analyses for the primary endpoint according to ANCOVA demonstrated the superiority of fremanezumab over placebo in Japanese patients (quarterly fremanezumab, p=0.0005; monthly fremanezumab, p=0.0002 in both trials). Results using the MMRM analysis confirmed the rapid onset of action in this population. Results of the secondary endpoints further supported the efficacy of fremanezumab in Japanese patients. Fremanezumab was well tolerated with nasopharyngitis and injection-site reactions representing the most common adverse events in all treatment groups.Conclusion: Despite the limitations of subgroup analyses, these consistent results confirm the efficacy and tolerability of fremanezumab in Japanese patients with CM.Keywords: calcitonin gene-related peptide, chronic migraine, fremanezumab, Japanese

Published
2023

3. Clinical Characteristics and Outcomes of Patients with Asthma–COPD Overlap in Japanese Patients with COPD

Author

Kobayashi S, Hanagama M, Ishida M, Ono M, Sato H, Yamanda S, and Yanai M

Subjects
asthma, asthma–copd overlap, copd, exacerbations, mortality, Diseases of the respiratory system, RC705-779
Abstract

Seiichi Kobayashi,1 Masakazu Hanagama,1 Masatsugu Ishida,1 Manabu Ono,1 Hikari Sato,1 Shinsuke Yamanda,1,2 Masaru Yanai1 1Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan; 2Department of Pulmonary Medicine, Sendai Kosei Hospital, Sendai, Miyagi, JapanCorrespondence: Seiichi KobayashiDepartment of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, 71 Nishimichishita, Hebita, Ishinomaki 986-8522, JapanTel +81 225 21 7220Fax +81 225 96 0122Email skoba-thk@umin.ac.jpPurpose: Asthma–COPD overlap (ACO) has been reported as an association with a lower quality of life, frequent exacerbations, and higher mortality than those with COPD alone. However, clinical characteristics and outcomes of ACO remain controversial.Patients and Methods: We conducted a prospective observational study analyzing data of patients with stable COPD enrolled from the Ishinomaki COPD Network Registry. Patients with features of asthma who had a history of respiratory symptoms that vary over time and intensity, together with documented variable expiratory airflow limitation, were identified, and then defined as having ACO. The characteristics, frequency of exacerbations, and mortality during the 3-year follow-up were compared between patients with ACO and patients with COPD alone.Results: Among 387 patients with COPD, 41 (10.6%) were identified as having ACO. Patients with ACO tended to be younger, have higher BMI, have a shorter smoking history, and use more respiratory medications, especially inhaled corticosteroids. Inflammatory biomarkers including fractional exhaled nitric oxide, blood eosinophil count, total immunoglobulin E (IgE) level, and presence of antigen-specific IgE were significantly higher in patients with ACO than in those with COPD alone. Lung function, mMRC score, CAT score, and comorbidity index were not different between the groups. The annual rate of all exacerbations and severe exacerbations required hospital admission were not different between ACO and COPD alone (0.20 vs 0.14, 0.12 vs 0.10, events per person, respectively). Mortality was significantly higher in patients with COPD alone compared with those with ACO during the study period (P=0.037).Conclusion: The results of our study indicate that ACO is not associated with poor clinical features nor outcomes in an outpatient COPD cohort receiving appropriate treatment.Keywords: asthma, asthma–COPD overlap, COPD, exacerbations, mortality

Published
2020

4. Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study

Author

Kawamata M, Iseki M, Kawakami M, Yabuki S, Sasaki T, Ishida M, Nishiyori A, Hida H, and Kikuchi S

Subjects
analgesics, chronic pain, japan, opioids, Medicine (General), R5-920
Abstract

Mikito Kawamata,1 Masako Iseki,2 Mamoru Kawakami,3 Shoji Yabuki,4 Takuma Sasaki,5 Mitsuhiro Ishida,5 Atsushi Nishiyori,5 Hideaki Hida,6 Shin-ichi Kikuchi4 1Department of Anesthesiology and Resuscitology, Shinshu University School of Medicine, Matsumoto, Japan; 2Department of Anesthesiology and Pain Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan; 3Spine Care Center, Wakayama Medical University Kihoku Hospital, Wakayama, Japan; 4Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan; 5Clinical Development Department, Shionogi & Co., Ltd., Osaka, Japan; 6Biostatistics Center, Shionogi & Co., Ltd., Osaka, JapanCorrespondence: Takuma SasakiClinical Development Department, Shionogi & Co., Ltd., 12F, Hankyu Terminal Bld., 1-4, Shibata 1-chome, Kita-ku, Osaka 530-0012, JapanTel +81-6-6485-5090Fax +81-6-6375-5780Email Takuma.sasaki@shionogi.co.jpPurpose: To assess the efficacy and safety of S-8117, an oral, controlled-release formulation of oxycodone hydrochloride, in Japanese patients with chronic non-cancer pain (CNCP).Patients and methods: In this multicenter, non-randomized, open-label, 2-part (part 1, dose-titration followed by maintenance period; part 2, long-term administration period) study at 38 centers in Japan (2013–2015), adult patients with CNCP for ≥12 weeks were administered S-8117. The primary endpoint was proportion of patients with successful maintenance of pain control in part 1 and long-term safety in part 2. Secondary endpoints included time to inadequate analgesia, rate of transition to the maintenance period, and discontinuation due to inadequate analgesia/adverse events (AEs), Brief Pain Inventory (BPI) pain severity, BPI pain interference, 36-item Short Form Health Survey (SF-36) score, and Western Ontario and McMaster Universities (WOMAC) index, Subjective Opioid Withdrawal Scale (SOWS), Clinical Opioid Withdrawal Scale (COWS), Dependency-2-A (D-2-A), and Dependency-2-B (D-2-B) questionnaires.Results: Of 130 patients (mean age, 63.6 years; women, 62.3%) in the dose-titration period, 95 entered the maintenance period; 60 of 83 who entered the long-term administration period completed it. The proportion of patients (95% confidence interval) with successful maintenance of pain control, transition to maintenance period, and discontinuation due to inadequate analgesia/AEs was 78.9% (69.4–86.6), 73.1% (64.6–80.5), and 21.1% (13.4–30.6), respectively. Time to inadequate analgesia could not be estimated. Changes from baseline in BPI, SF-36, and WOMAC index scores suggested improvements in pain relief and quality of life. Based on the SOWS, COWS, D-2-A and D-2-B questionnaires, no patient developed clinically relevant withdrawal syndrome or was ascertained to have developed drug dependence. Overall, the incidence of treatment-emergent AEs (TEAEs) was 93.8%; most common TEAEs were constipation (49.2%), nausea (42.3%), nasopharyngitis (34.6%), and somnolence (32.3%).Conclusion: These results demonstrate the efficacy and safety of S-8117 in Japanese patients with CNCP.Keywords: analgesics, chronic pain, Japan, opioids

Published
2019

5. Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study

Author

Kawamata M, Iseki M, Kawakami M, Yabuki S, Sasaki T, Ishida M, Nishiyori A, Hida H, and Kikuchi S

Subjects
chronic low back pain, opioids, oxycodone, Medicine (General), R5-920
Abstract

Mikito Kawamata,1 Masako Iseki,2 Mamoru Kawakami,3 Shoji Yabuki,4 Takuma Sasaki,5 Mitsuhiro Ishida,5 Atsushi Nishiyori,5 Hideaki Hida,6 Shin-ichi Kikuchi4 1Department of Anesthesiology and Resuscitology, Shinshu University School of Medicine, Matsumoto, Japan; 2Department of Anesthesiology and Pain Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan; 3Spine Care Center, Wakayama Medical University Kihoku Hospital, Wakayama, Japan; 4Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan; 5Clinical Development Department, Shionogi & Co. Ltd., Osaka, Japan; 6Biostatistics Center, Shionogi & Co. Ltd., Osaka, Japan Background: Oxycodone is one of the options for the management of CLBP in patients with an inadequate response to other analgesics. However, oxycodone is not yet approved for noncancer pain in Japan. Here, we assessed the efficacy and long-term safety of S-8117, a controlled-release oxycodone formulation, for the management of Japanese CLBP patients. Patients and methods: An initial enriched enrollment randomized withdrawal, double-blind, placebo-controlled, 5-week phase III trial was conducted across 54 centers in Japan to assess the efficacy of S-8117 vs placebo in moderate-to-severe CLBP patients. Subsequently, a 52-week, open-label, single-arm study was conducted across 53 centers in Japan to evaluate the long-term safety of S-8117. The primary endpoint was the time to inadequate analgesic response during 35 days of the double-blind period. Secondary endpoints were the percentages of patients with inadequate analgesic response, discontinuation rate due to inadequate analgesic effects or AEs, and changes in scores of BPI severity, BPI pain interference, SF-36, and Roland-Morris Disability Questionnaire. Safety was assessed as the incidence of AEs and ADRs. Results: Of the 189 patients enrolled in the double-blind study, 130 patients who completed the initial titration period were randomized 1:1 to receive either S-8117 (n=62) or placebo (n=68). Baseline characteristics were comparable across the study groups. The time to inadequate analgesic response was significantly longer in patients treated with S-8117 than placebo (P=0.0095). Secondary endpoints corroborated the efficacy of S-8117 vs placebo. Overall, 478 AEs were reported in 73/75 patients in the long-term study. The most frequent ADRs were somnolence, constipation, and nausea. No case of drug dependence was reported in the long-term study. Conclusion: Short-term efficacy vs placebo and long-term safety of S-8117 were demonstrated for the management of Japanese patients with moderate-to-severe CLBP. Keywords: chronic low back pain, opioids, oxycodone, RCT

Published
2019

6. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry

Author

Kobayashi S, Hanagama M, Ishida M, Sato H, Ono M, Yamanda S, Yamada M, Aizawa H, and Yanai M

Subjects
COPD, GOLD, GOLD 2017, exacerbations, mortality, Diseases of the respiratory system, RC705-779
Abstract

Seiichi Kobayashi,1 Masakazu Hanagama,1 Masatsugu Ishida,1 Hikari Sato,1 Manabu Ono,1 Shinsuke Yamanda,1 Mitsuhiro Yamada,2 Hiroyuki Aizawa,1 Masaru Yanai1 1Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan; 2Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan Purpose: The GOLD report provides a framework for classifying COPD in a way that reflects its clinical impact and allows treatment recommendations. The GOLD 2017 proposes a new classification whereby patients are grouped as A–D according to their symptoms and history of exacerbations. However, the clinical characteristics and outcomes in these patients are not well documented.Patients and methods: In this prospective observational study, we analyzed data from the Ishinomaki COPD Network Registry. All patients with stable COPD were classified into the four groups defined by GOLD 2017. The patient demographics, clinical characteristics, number of exacerbations, and mortality rate during 1 year of follow-up were compared between the groups.Results: Four hundred and one patients with stable COPD were identified. There were 240 patients (59.9%) in group A, 122 (30.4%) in group B, 16 (4.0%) in group C, and 23 (5.7%) in group D. Patients in groups B, C, and D had ORs of 2.95, 3.92, and 5.45, respectively, for risk of exacerbation relative to group A. Groups C and D experienced exacerbations more frequently, including exacerbations leading to hospital admission, than groups A and B (both P

Published
2018

7. Response to duloxetine in patients with knee pain due to osteoarthritis: an exploratory post hoc analysis of a Japanese Phase III randomized study

Author

Itoh N, Tsuji T, Ishida M, Ochiai T, Konno S, and Uchio Y

Subjects
Brief Pain Inventory, Responder analysis, WOMAC, Medicine (General), R5-920
Abstract

Naohiro Itoh,1 Toshinaga Tsuji,1 Mitsuhiro Ishida,2 Toshimitsu Ochiai,3 Shinichi Konno,4 Yuji Uchio5 1Medical Affairs Department, Shionogi & Co. Ltd, Osaka, Japan; 2Clinical Development Department, Shionogi & Co. Ltd, Osaka, Japan; 3Biostatistics Center, Shionogi & Co. Ltd, Osaka, Japan; 4Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, Japan; 5Department of Orthopaedic Surgery, Shimane University School of Medicine, Shimane, Japan Purpose: To assess whether patients with knee osteoarthritis pain who have early pain reduction or treatment-related adverse events of special interest (TR-AESIs; constipation, decreased appetite, malaise, nausea, somnolence, thirst) with duloxetine treatment are more likely to have later improvements in pain and quality of life (QOL) relative to placebo than patients without these early indicators.Patients and methods: This was a post hoc analysis of 14-week randomized trial of Japanese patients with knee osteoarthritis pain (Brief Pain Inventory [BPI]-Severity average pain score ≥4) receiving duloxetine 60 mg/day (n=177 analyzed) or placebo (n=176). Primary trial outcome was change from baseline in BPI-Severity average pain at Week 14. Subgroups included early pain reduction (≥30%, 10%–30%, or

Published
2018

8. Duloxetine in patients with diabetic peripheral neuropathic pain in Japan: a randomized, double-blind, noninferiority comparative study with pregabalin

Author

Enomoto H, Yasuda H, Nishiyori A, Fujikoshi S, Furukawa M, Ishida M, Takahashi M, Tsuji T, Yoshikawa A, and Alev L

Subjects
serotonin and norepinephrine reuptake inhibitor, diabetic peripheral neuropathic pain, duloxetine, Japan, noninferiority, pregabalin, Medicine (General), R5-920
Abstract

Hiroyuki Enomoto,1 Hitoshi Yasuda,2 Atsushi Nishiyori,3 Shinji Fujikoshi,4 Masashi Furukawa,5 Mitsuhiro Ishida,6 Masashi Takahashi,1 Toshinaga Tsuji,7 Aki Yoshikawa,8 Levent Alev9 1Bio-Medicine, Medicines Development Unit, Eli Lilly Japan K.K, Tokyo, Japan; 2Foundation of Shiga Health Research Center, Shiga, Japan; 3Project Management, Global Development Division, Shionogi & Co. Ltd., Osaka, Japan; 4Statistical Science, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan; 5Biostatistics, Biostatistics Department, Shionogi & Co. Ltd., Osaka, Japan; 6Clinical Research Development, Shionogi & Co. Ltd., Osaka, Japan; 7Medical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan; 8Scientific Communications, Medicines Development Unit, Eli Lilly Japan K.K, Kobe, Japan; 9Eli Lilly, Medical Department, Lilly Turkey, Istanbul, Turkey Purpose: Duloxetine and pregabalin are recommended as first-line treatments for diabetic peripheral neuropathic pain (DPNP). However, studies have not reported a direct comparison between duloxetine and pregabalin. We conducted a postmarketing, randomized, double-blind study to assess the noninferiority of duloxetine compared with pregabalin after 12 weeks of treatment in adult patients with DPNP in Japan (NCT02417935). Patients and methods: Patients (N = 303) with distal symmetrical DPNP were randomized to and were administered duloxetine (40–60 mg/day) or pregabalin (300–600 mg/day). The primary endpoint was the change from baseline in weekly mean of the 24-hour average pain score (numeric rating scale [NRS]). Noninferiority of duloxetine compared with pregabalin was assessed with the primary endpoint at week 12. Secondary measures, including night pain and worst pain, Brief Pain Inventory-Severity and Interference rating short form (BPI-SF), Clinical Global Impression of Improvement (CGI-I), Patient Global Impression of Improvement (PGI-I), and Neuropathic Pain Symptom Inventory (NPSI), health outcome measures (EuroQol 5-Dimension index and VAS), and safety were also assessed. Results: For the 24-hour NRS average pain score, the difference between the duloxetine and pregabalin groups was 0.072 (95% CI: – 0.295, 0.439), and the upper bound of the 95% CI (0.439) did not exceed the predefined noninferiority margin (0.51), at the end of the study period. For secondary outcome measures (night pain, worst pain, BPI-SF, CGI-I, PGI-I, NPSI) and health outcome measures, both the duloxetine and pregabalin treatment groups showed an improvement from baseline with no significant between-group difference. Duloxetine and pregabalin were well tolerated and the safety profiles were consistent with previously reported results. Conclusion: This study demonstrated the noninferior efficacy of duloxetine compared with pregabalin in the treatment of adult patients with DPNP. The safety analyses showed an acceptable tolerability based on safety profiles of duloxetine and pregabalin. Keywords: serotonin and norepinephrine reuptake inhibitor, diabetic peripheral neuropathic pain, duloxetine, Japan, noninferiority, pregabalin

Published
2018

9. Safety and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis: an open-label, long-term, Phase III extension study

Author

Uchio Y, Enomoto H, Ishida M, Tsuji T, Ochiai T, and Konno S

Subjects
Analgesics, Chronic pain due to knee osteoarthritis, Duloxetine, Quality of life, Western Ontario and McMaster Universities Osteoarthritis Index, Medicine (General), R5-920
Abstract

Yuji Uchio,1 Hiroyuki Enomoto,2 Mitsuhiro Ishida,3 Toshinaga Tsuji,4 Toshimitsu Ochiai,5 Shinichi Konno6 1Department of Orthopaedic Surgery, Shimane University School of Medicine, Shimane, Japan; 2Bio-medicine, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, Japan; 3Clinical Research Development, Shionogi & Co. Ltd, Osaka, Japan; 4Medical Affairs Department, Shionogi & Co. Ltd, Osaka, Japan; 5Biostatistics Center, Shionogi & Co. Ltd, Osaka, Japan; 6Department of Orthopaedic Surgery, Fukushima Medical University, Fukushima, Japan Purpose: To assess long-term safety, tolerability, and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis. Methods: In this open-label extension study (NCT02335346), Japanese patients with knee osteoarthritis and pain (Brief Pain Inventory [BPI] – Severity average pain score ≥4 at start of randomized trial) who had previously received duloxetine 60 mg/day or placebo for 14 weeks in a double-blind randomized trial entered the extension and received duloxetine 60 mg/day for 48 weeks. The primary outcome was safety/tolerability, secondary outcomes were change in BPI-Severity (BPI-S) average pain, BPI-Interference (BPI-I), Patient Global Impression-Improvement (PGI-I), Clinical Global Impression-Improvement (CGI-I), 36-item Short-Form Health Survey (SF36), and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and exploratory outcomes were knee range of motion (efficacy outcome) and Kellgren–Lawrence grade (safety outcome). Results: Of 323 patients who completed the randomized trial, 93 (50 placebo, 43 duloxetine) entered the extension. Most patients (85, 91.4%) experienced an adverse event, most commonly constipation, nasopharyngitis, somnolence, and dry mouth (≥10% of patients). There were eight serious adverse events in seven patients and no deaths. No obvious duloxetine-related changes were observed in laboratory tests, vital signs, or electrocardiograms. The change from baseline in BPI-S average pain score was significant throughout the extension. Significant reductions in BPI-I, PGI-I, CGI-I, WOMAC, and SF36 scores were also maintained through 52 weeks. There were no substantial changes in range of motion or Kellgren–Lawrence grade. Conclusion: In Japanese patients with chronic knee pain due to osteoarthritis, long-term treatment with duloxetine was well tolerated and associated with sustained improvements in pain and health-related quality of life without radiographic deterioration. Keywords: analgesics, chronic pain due to knee osteoarthritis, duloxetine, quality of life, Western Ontario and McMaster Universities Osteoarthritis Index

Published
2018

10. Response to duloxetine in chronic low back pain: exploratory post hoc analysis of a Japanese Phase III randomized study

Author

Tsuji T, Itoh N, Ishida M, Ochiai T, and Konno S

Subjects
Brief Pain Inventory, Chronic low back pain, Duloxetine, Low back pain, Quality of life, Medicine (General), R5-920
Abstract

Toshinaga Tsuji,1 Naohiro Itoh,1 Mitsuhiro Ishida,2 Toshimitsu Ochiai,3 Shinichi Konno4 1Medical Affairs Department, 2Clinical Research Development, 3Biostatistics Department, Shionogi & Co. Ltd, Osaka, 4Department of Orthopedic Surgery, Fukushima Medical University, Fukushima, Japan Purpose: Duloxetine is efficacious for chronic low back pain (CLBP). This post hoc analysis of a Japanese randomized, placebo-controlled trial (ClinicalTrials.gov, NCT01855919) assessed whether patients with CLBP with early pain reduction or treatment-related adverse events of special interest (TR-AESIs; nausea, somnolence, constipation) have enhanced responses to duloxetine. Patients and methods: Patients (N = 456) with CLBP for ≥6 months and Brief Pain Inventory (BPI) average pain severity score of ≥4 were randomized (1:1) to duloxetine 60 mg/day or placebo for 14 weeks. Primary outcome was change from baseline in BPI average pain severity score (pain reduction). Subgroup analyses included early pain reduction (≥30%, 10%–30%, or

Published
2017

11. Duloxetine 60 mg for chronic low back pain: post hoc responder analysis of double-blind, placebo-controlled trials

Author

Alev L, Fujikoshi S, Yoshikawa A, Enomoto H, Ishida M, Tsuji T, Ogawa K, and Konno S

Subjects
Brief Pain Inventory, Chronic pain, Duloxetine hydrochloride, Low back pain, Michigan Body Map, Responder analysis, Medicine (General), R5-920
Abstract

Levent Alev,1 Shinji Fujikoshi,2 Aki Yoshikawa,3 Hiroyuki Enomoto,1 Mitsuhiro Ishida,4 Toshinaga Tsuji,5 Kei Ogawa,1 Shinichi Konno6 1Bio-Medicine, 2Statistical Science, 3Scientific Communications, Medicines Development Unit, Eli Lilly Japan K.K., Kobe, 4Clinical Research Development, 5Medical Affairs Department, Shionogi & Co. Ltd, Osaka, 6Department of Orthopedic Surgery, Fukushima Medical University, Fukushima, Japan Introduction: Duloxetine has demonstrated efficacy in chronic low back pain (CLBP). We examined the predictors of response to duloxetine for CLBP.Patients and methods: This was a post hoc analysis of pooled data from 4 double-blind, randomized, placebo-controlled trials of duloxetine (60 mg/day for 12–14 weeks) in adult patients with CLBP. Primary outcome was proportion of patients with ≥30% reduction in Brief Pain Inventory (BPI) average pain (“pain reduction”) at 12–14 weeks. The proportion of patients with ≥30% and ≥50% (secondary outcome) pain reduction in duloxetine and placebo groups was compared. Variables for responder analyses were early improvement (≥15% pain reduction at Week 2), sex, age, baseline BPI average pain score, duration of CLBP, and number of painful body sites according to the Michigan Body Map (≥2 vs 1 [isolated CLBP]; 1 trial); relative risk (RR) and 95% confidence interval (CI) were calculated.Results: Compared with placebo (n = 653), a greater proportion of duloxetine-treated patients (n = 642) achieved ≥30% (59.7% vs 47.8%; P < 0.001) and ≥50% pain reduction (48.6% vs 35.1%; P < 0.001). Among duloxetine-treated patients, early improvement was associated with greater likelihood of ≥30% (RR [95% CI], 2.91 [2.30–3.67]) or ≥50% (3.24 [2.44–4.31]) pain reduction. Women were slightly more likely than men to achieve ≥30% (RR [95% CI], 1.14 [1.00–1.30]) or ≥50% (1.17 [0.99–1.38]) pain reduction. Response rates were similar between age, CLBP duration, and baseline BPI average pain score subgroups. Patients with ≥2 painful sites were more likely to respond to duloxetine 60 mg relative to placebo than patients with isolated CLBP (RR, duloxetine vs placebo [95% CI]: ≥30% reduction, ≥2 painful sites 1.40 [1.18–1.66], isolated CLBP 1.07 [0.78–1.48]; ≥50% reduction, ≥2 painful sites 1.51 [1.20–1.89], isolated CLBP 1.23 [0.81–1.88]).Conclusion: Early pain reduction was indicative of overall response. Patients with multiple painful sites had more benefit from duloxetine than patients with isolated CLBP. Keywords: Brief Pain Inventory, chronic pain, SNRI, low back pain, Michigan Body Map, multiple painful sites

Published
2017

12. Inflammatory biomarkers in asthma-COPD overlap syndrome

Author

Kobayashi S, Hanagama M, Yamanda S, Ishida M, and Yanai M

Subjects
asthma, asthma-COPD overlap syndrome, COPD, biomarkers, Diseases of the respiratory system, RC705-779
Abstract

Seiichi Kobayashi, Masakazu Hanagama, Shinsuke Yamanda, Masatsugu Ishida, Masaru YanaiDepartment of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, JapanBackground: The clinical phenotypes and underlying mechanisms of asthma-COPD overlap syndrome (ACOS) remain elusive. This study aimed to investigate a comparison of COPD patients with and without ACOS, focusing on inflammatory biomarkers, in an outpatient COPD cohort.Methods: We conducted a cross-sectional study analyzing prospectively collected data from the Ishinomaki COPD Network registry. All participants were diagnosed with COPD, confirmed by using spirometry, and were aged 40–90 years and former smokers. Patients with features of asthma including both variable respiratory symptoms and variable expiratory airflow limitation were identified and defined as having ACOS. Then, the inflammatory biomarkers such as fractional exhaled nitric oxide level, blood eosinophil count and percentage, total immunoglobulin E (IgE) level, and presence of antigen-specific IgE were evaluated.Results: A total of 257 patients with COPD were identified, including 37 (14.4%) with ACOS. Patients with ACOS tended to be younger, have a shorter smoking history, and use more respiratory medications, especially inhaled corticosteroids and theophylline. Mean fractional exhaled nitric oxide level was significantly higher in those with ACOS than in those without ACOS (38.5 parts per billion [ppb] vs 20.3 ppb, P

Published
2016

13. Scaling slowly rotating asteroids by stellar occultations

Author

Marciniak, A., Ďurech, J., Choukroun, A., Hanuš, J., Ogłoza, W., Szakáts, R., Molnár, L., Pál, A., Monteiro, F., Frappa, E., Beisker, W., Pavlov, H., Moore, J., Adomavičienė, R., Aikawa, R., Andersson, S., Antonini, P., Argentin, Y., Asai, A., Assoignon, P., Barton, J., Baruffetti, P., Bath, K. L., Behrend, R., Benedyktowicz, L., Bernasconi, L., Biguet, G., Billiani, M., Błażewicz, D., Boninsegna, R., Borkowski, M., Bosch, J., Brazill, S., Bronikowska, M., Bruno, A., Bąk, M. Butkiewicz, Caron, J., Casalnuovo, G., Castellani, J. J., Ceravolo, P., Conjat, M., Delincak, P., Delpau, J., Demeautis, C., Demirkol, A., Dróżdż, M., Duffard, R., Durandet, C., Eisfeldt, D., Evangelista, M., Fauvaud, S., Fauvaud, M., Ferrais, M., Filipek, M., Fini, P., Fukui, K., Gährken, B., Geier, S., George, T., Goffin, B., Golonka, J., Goto, T., Grice, J., Guhl, K., Halíř, K., Hanna, W., Harman, M., Hashimoto, A., Hasubick, W., Higgins, D., Higuchi, M., Hirose, T., Hirsch, R., Hofschulz, O., Horaguchi, T., Horbowicz, J., Ida, M., Ignácz, B., Ishida, M., Isobe, K., Jehin, E., Joachimczyk, B., Jones, A., Juan, J., Kamiński, K., Kamińska, M. K., Kankiewicz, P., Kasebe, H., Kattentidt, B., Kim, D. -H., Kim, M. -J., Kitazaki, K., Klotz, A., Komraus, M., Konstanciak, I., Tóth, R. Könyves, Kouno, K., Kowald, E., Krajewski, J., Krannich, G., Kreutzer, A., Kryszczyńska, A., Kubánek, J., Kudak, V., Kugel, F., Kukita, R., Kulczak, P., Lazzaro, D., Licandro, J., Livet, F., Maley, P., Manago, N., Mánek, J., Manna, A., Matsushita, H., Meister, S., Mesquita, W., Messner, S., Michelet, J., Michimani, J., Mieczkowska, I., Morales, N., Motyliński, M., Murawiecka, M., Newman, J., Nikitin, V., Nishimura, M., Oey, J., Oszkiewicz, D., Owada, M., Pakštienė, E., Pawłowski, M., Pereira, W., Perig, V., Perła, J., Pilcher, F., Podlewska-Gaca, E., Polák, J., Polakis, T., Polińska, M., Popowicz, A., Richard, F., Rives, J. J., Rodrigues, T., Rogiński, Ł., Rondón, E., Rottenborn, M., Schäfer, R., Schnabel, C., Schreurs, O., Selva, A., Simon, M., Skiff, B., Skrutskie, M., Skrzypek, J., Sobkowiak, K., Sonbas, E., Sposetti, S., Stuart, P., Szyszka, K., Terakubo, K., Thomas, W., Trela, P., Uchiyama, S., Urbanik, M., Vaudescal, G., Venable, R., Watanabe, Ha., Watanabe, Hi., Winiarski, M., Wróblewski, R., Yamamura, H., Yamashita, M., Yoshihara, H., Zawilski, M., Zelený, P., Żejmo, M., Żukowski, K., and Żywica, S.

Subjects
Astrophysics - Earth and Planetary Astrophysics
Abstract

As evidenced by recent survey results, majority of asteroids are slow rotators (P>12 h), but lack spin and shape models due to selection bias. This bias is skewing our overall understanding of the spins, shapes, and sizes of asteroids, as well as of their other properties. Also, diameter determinations for large (>60km) and medium-sized asteroids (between 30 and 60 km) often vary by over 30% for multiple reasons. Our long-term project is focused on a few tens of slow rotators with periods of up to 60 hours. We aim to obtain their full light curves and reconstruct their spins and shapes. We also precisely scale the models, typically with an accuracy of a few percent. We used wide sets of dense light curves for spin and shape reconstructions via light-curve inversion. Precisely scaling them with thermal data was not possible here because of poor infrared data: large bodies are too bright for WISE mission. Therefore, we recently launched a campaign among stellar occultation observers, to scale these models and to verify the shape solutions, often allowing us to break the mirror pole ambiguity. The presented scheme resulted in shape models for 16 slow rotators, most of them for the first time. Fitting them to stellar occultations resolved previous inconsistencies in size determinations. For around half of the targets, this fitting also allowed us to identify a clearly preferred pole solution, thus removing the ambiguity inherent to light-curve inversion. We also address the influence of the uncertainty of the shape models on the derived diameters. Overall, our project has already provided reliable models for around 50 slow rotators. Such well-determined and scaled asteroid shapes will, e.g. constitute a solid basis for density determinations when coupled with mass information. Spin and shape models continue to fill the gaps caused by various biases., Comment: Accepted to Astronomy & Astrophysics. 12 pages + appendices

Published
2023
Full Text
View/download PDF

14. Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension

Author

Yagi S, Takashima A, Mitsugi M, Wada T, Hotchi J, Aihara K, Hara T, Ishida M, Fukuda D, Ise T, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, and Sata M

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Shusuke Yagi,1 Akira Takashima,1 Minoru Mitsugi,2 Toshihiro Wada,2 Junko Hotchi,1 Ken-ichi Aihara,3 Tomoya Hara,1 Masayoshi Ishida,1 Daiju Fukuda,4 Takayuki Ise,1 Koji Yamaguchi,1 Takeshi Tobiume,1 Takashi Iwase,1 Hirotsugu Yamada,1 Takeshi Soeki,1 Tetsuzo Wakatsuki,1 Michio Shimabukuro,4 Masashi Akaike,5 Masataka Sata11Department of Cardiovascular Medicine, Graduate School of Health Biosciences, University of Tokushima, Tokushima, 2Department of Internal Medicine, Shikoku Central Hospital, Shikokuchuo, 3Department of Medicine and Bioregulatory Sciences, 4Department of Cardio-Diabetes Medicine, 5Department of Medical Education, Graduate School of Health Biosciences, University of Tokushima, Tokushima, JapanBackground: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension.Keywords: blood pressure, combination tablet, uric acid, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol

Published
2015

15. The design and performance of the XL-Calibur anticoincidence shield

Author

Iyer, N. K., Kiss, M., Pearce, M., Stana, T. -A., Awaki, H., Bose, R. G., Dasgupta, A., De Geronimo, G., Gau, E., Hakamata, T., Ishida, M., Ishiwata, K., Kamogawa, W., Kislat, F., Kitaguchi, T., Krawczynski, H., Lisalda, L., Maeda, Y., Matsumoto, H., Miyamoto, A., Miyazawa, T., Mizuno, T., Rauch, B. F., Cavero, N. Rodriguez, Sakamoto, N., Sato, J., Spooner, S., Takahashi, H., Takeo, M., Tamagawa, T., Uchida, Y., West, A. T., Wimalasena, K., and Yoshimoto, M.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Physics - Instrumentation and Detectors
Abstract

The XL-Calibur balloon-borne hard X-ray polarimetry mission comprises a Compton-scattering polarimeter placed at the focal point of an X-ray mirror. The polarimeter is housed within a BGO anticoincidence shield, which is needed to mitigate the considerable background radiation present at the observation altitude of ~40 km. This paper details the design, construction and testing of the anticoincidence shield, as well as the performance measured during the week-long maiden flight from Esrange Space Centre to the Canadian Northwest Territories in July 2022. The in-flight performance of the shield followed design expectations, with a veto threshold <100 keV and a measured background rate of ~0.5 Hz (20-40 keV). This is compatible with the scientific goals of the mission, where %-level minimum detectable polarisation is sought for a Hz-level source rate., Comment: Submitted to Nuclear Instruments and Methods A

Published
2022
Full Text
View/download PDF

18. XL-Calibur -- a second-generation balloon-borne hard X-ray polarimetry mission

Author

Abarr, Q., Awaki, H., Baring, M. G., Bose, R., De Geronimo, G., Dowkontt, P., Errando, M., Guarino, V., Hattori, K., Hayashida, K., Imazato, F., Ishida, M., Iyer, N. K., Kislat, F., Kiss, M., Kitaguchi, T., Krawczynski, H., Lisalda, L., Matake, H., Maeda, Y., Matsumoto, H., Mineta, T., Miyazawa, T., Mizuno, T., Okajima, T., Pearce, M., Rauch, B. F., Ryde, F., Shreves, C., Spooner, S., Stana, T. -A., Takahashi, H., Takeo, M., Tamagawa, T., Tamura, K., Tsunemi, H., Uchida, N., Uchida, Y., West, A. T., Wulf, E. A., and Yamamoto, R.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

XL-Calibur is a hard X-ray (15-80 keV) polarimetry mission operating from a stabilised balloon-borne platform in the stratosphere. It builds on heritage from the X-Calibur mission, which observed the accreting neutron star GX 301-2 from Antarctica, between December 29th 2018 and January 1st 2019. The XL-Calibur design incorporates an X-ray mirror, which focusses X-rays onto a polarimeter comprising a beryllium rod surrounded by Cadmium Zinc Telluride (CZT) detectors. The polarimeter is housed in an anticoincidence shield to mitigate background from particles present in the stratosphere. The mirror and polarimeter-shield assembly are mounted at opposite ends of a 12 m long lightweight truss, which is pointed with arcsecond precision by WASP - the Wallops Arc Second Pointer. The XL-Calibur mission will achieve a substantially improved sensitivity over X-Calibur by using a larger effective area X-ray mirror, reducing background through thinner CZT detectors, and improved anticoincidence shielding. When observing a 1 Crab source for $t_{\rm day}$ days, the Minimum Detectable Polarisation (at 99% confidence level) is $\sim$2$\%\cdot t_{\rm day}^{-1/2}$. The energy resolution at 40 keV is $\sim$5.9 keV. The aim of this paper is to describe the design and performance of the XL-Calibur mission, as well as the foreseen science programme., Comment: 19 pages, 17 figures. Accepted for publication in Astroparticle Physics

Published
2020
Full Text
View/download PDF

19. Super DIOS Project for Exploring “Dark Baryon”

Author

Sato, K., Yamasaki, N. Y., Ishida, M., Maeda, Y., Mitsuda, K., Ishisaki, Y., Fujita, Y., Ezoe, Y., Mitsuishi, I., Tawara, Y., Osato, K., Kawai, N., Matsushita, K., Nagai, D., Yoshikawa, K., Fujimoto, R., Tsuru, T. G., Ota, N., Yamada, S., Ichinohe, Y., Uchida, Y., and Nakashima, Y.

Published
2022
Full Text
View/download PDF

20. Inorbit Performance of the Hard X-ray Telescope (HXT) on board the Hitomi (ASTRO-H) satellite

Author

Matsumoto, H., Awaki, H., Ishida, M., Furuzawa, A., Yamauchi, S., Maeda, Y., Mitsuishi, I., Haba, Y., Hayashi, T., Iizuka, R., Ishibashi, K., Itoh, M., Kunieda, H., Miyazawa, T., Mori, H., Okajima, T., Sugita, S., Tamura., K., and Tawara, Y.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

Hitomi (ASTRO-H) carries two Hard X-ray Telescopes (HXTs) that can focus X-rays up to 80 keV. Combined with the Hard X-ray Imagers (HXIs) that detect the focused X-rays, imaging spectroscopy in the high-energy band from 5 keV to 80 keV is made possible. We studied characteristics of HXTs after the launch such as the encircled energy function (EEF) and the effective area using the data of a Crab observation. The half power diameters (HPDs) in the 5--80 keV band evaluated from the EEFs are 1.59 arcmin for HXT-1 and 1.65 arcmin for HXT-2. Those are consistent with the HPDs measured with ground experiments when uncertainties are taken into account. We can conclude that there is no significant change in the characteristics of the HXTs before and after the launch. The off-axis angle of the aim point from the optical axis is evaluated to be less than 0.5 arcmin for both HXT-1 and HXT-2. The best-fit parameters for the Crab spectrum obtained with the HXT-HXI system are consistent with the canonical values., Comment: 13 pages, 5 figures; the acknowledgment was modified

Published
2018
Full Text
View/download PDF

23. In-orbit performance of the soft X-ray imaging system aboard Hitomi (ASTRO-H)

Author

Nakajima, H., Maeda, Y., Uchida, H., Tanaka, T., Tsunemi, H., Hayashida, K., Tsuru, T. G., Dotani, T., Nagino, R., Inoue, S., Ozaki, M., Tomida, H., Natsukari, C., Ueda, S., Mori, K., Yamauchi, M., Hatsukade, I., Nishioka, Y., Sakata, M., Beppu, T., Honda, D., Nobukawa, M., Hiraga, J. S., Kohmura, T., Murakami, H., Nobukawa, K. K., Bamba, A., Doty, J. P., Iizuka, R., Sato, T., Kurashima, S., Nakaniwa, N., Asai, R., Ishida, M., Mori, H., Soong, Y., Okajima, T., Serlemitsos, P., Tawara, Y., Mitsuishi, I., Ishibashi, K., Tamura, K., Hayashi, T., Furuzawa, A., Sugita, S., Miyazawa, T., Awaki, H., Miller, E. D., and Yamaguchi, H.

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

We describe the in-orbit performance of the soft X-ray imaging system consisting of the Soft X-ray Telescope and the Soft X-ray Imager aboard Hitomi. Verification and calibration of imaging and spectroscopic performance are carried out making the best use of the limited data of less than three weeks. Basic performance including a large field of view of 38'x38' is verified with the first light image of the Perseus cluster of galaxies. Amongst the small number of observed targets, the on-minus-off pulse image for the out-of-time events of the Crab pulsar enables us to measure a half power diameter of the telescope as about 1.3'. The average energy resolution measured with the onboard calibration source events at 5.89 keV is 179 pm 3 eV in full width at half maximum. Light leak and cross talk issues affected the effective exposure time and the effective area, respectively, because all the observations were performed before optimizing an observation schedule and parameters for the dark level calculation. Screening the data affected by these two issues, we measure the background level to be 5.6x10^{-6} counts s^{-1} arcmin^{-2} cm^{-2} in the energy band of 5-12 keV, which is seven times lower than that of the Suzaku XIS-BI., Comment: Accepted for publication in PASJ. 17 pages, 18 figures

Published
2017
Full Text
View/download PDF

24. Discovery of Rapidly Moving Partial X-ray Absorbers within gamma Cassiopeiae

Author

Hamaguchi, K., Oskinova, L., Russell, C. M. P., Petre, R., Enoto, T., Morihana, K., and Ishida, M.

Subjects
Astrophysics - High Energy Astrophysical Phenomena, Astrophysics - Solar and Stellar Astrophysics
Abstract

Gamma Cassiopeiae is an enigmatic Be star with unusually strong hard X-ray emission. The Suzaku observatory detected six rapid X-ray spectral hardening events called "softness dips" in a ~100 ksec duration observation in 2011. All the softness dip events show symmetric softness ratio variations, and some of them have flat bottoms apparently due to saturation. The softness dip spectra are best described by either ~40% or ~70% partial covering absorption to kT ~12 keV plasma emission by matter with a neutral hydrogen column density of ~2-8e21 cm-2, while the spectrum outside of these dips is almost free of absorption. This result suggests the presence of two distinct X-ray emitting spots in the gamma Cas system, perhaps on a white dwarf companion with dipole mass accretion. The partial covering absorbers may be blobs in the Be stellar wind, the Be disk, or rotating around the white dwarf companion. Weak correlations of the softness ratios to the hard X-ray flux suggest the presence of stable plasmas at kT ~0.9 and 5 keV, which may originate from the Be or white dwarf winds. The formation of a Be star and white dwarf binary system requires mass transfer between two stars; gamma Cas may have experienced such activity in the past., Comment: 16 pages, 5 figures, accepted for publication in Astrophysical Journal

Published
2016
Full Text
View/download PDF

25. Flexible heat-flow sensing sheets based on the longitudinal spin Seebeck effect using one-dimensional spin-current conducting films

Author

Kirihara, A., Kondo, K., Ishida, M., Ihara, K., Iwasaki, Y., Someya, H., Matsuba, A., Uchida, K., Saitoh, E., Yamamoto, N., Kohmoto, S., and Murakami, T.

Subjects
Condensed Matter - Materials Science
Abstract

We demonstrated a flexible thermoelectric (TE) sheet based on the longitudinal spin Seebeck effect (LSSE) that is especially suitable for heat-flow sensing applications. This TE sheet contained a Ni0.2Zn0.3Fe2.5O4 film which was formed on a flexible plastic sheet using a spray-coating method known as ferrite plating. The experimental results suggest that the ferrite-plated film, which has a columnar crystal structure aligned perpendicular to the film plane, functions as a unique one-dimensional spin-current conductor suitable for bendable LSSE-based sensors.

Published
2016
Full Text
View/download PDF

26. Development of an IoT-Based Monitoring System for Healthcare: A Preliminary Study

Author

Ishida, M., Ushioda, S., Nagasawa, Y., Komuroa, Y., Tang, Z., Hu, L., Tamura, T., Sakatani, K., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Lambris, John D., Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Ryu, Pan-Dong, editor, LaManna, Joseph C., editor, Harrison, David K., editor, and Lee, Sang-Suk, editor

Published
2020
Full Text
View/download PDF

27. Relationship Between Cerebral Blood Oxygenation and Electrical Activity During Mental Stress Tasks: Simultaneous Measurements of NIRS and EEG

Author

Nagasawa, Y., Ishida, M., Komuro, Y., Ushioda, S., Hu, L., Sakatani, K., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Lambris, John D., Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Ryu, Pan-Dong, editor, LaManna, Joseph C., editor, Harrison, David K., editor, and Lee, Sang-Suk, editor

Published
2020
Full Text
View/download PDF

28. ASTRO-H White Paper - White Dwarf

Author

Mukai, K., Yuasa, T., Harayama, A., Hayashi, T., Ishida, M., Long, K. S., Terada, Y., and Tsujimoto, M.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Interacting binaries in which a white dwarf accretes material from a companion --- cataclysmic variables (CVs) in which the mass loss is via Roche-lobe overflow, and symbiotic stars in which the white dwarf captures the wind of a late type giant --- are relatively commonplace. They display a wide range of behaviors in the optical, X-rays, and other wavelengths, which still often baffles observers and theorists alike. They are likely to be a significant contributor to the Galactic ridge X-ray emission, and the possibility that some CVs or symbiotic stars may be the progenitors of some of the Type Ia supernovae deserves serious consideration. Furthermore, these binaries serve as excellent laboratories in which to study physics of X-ray emission from high density plasma, accretion physics, reflection, and particle acceleration. ASTRO-H is well-matched to the study of X-ray emission from many of these objects. In particular, the excellent spectral resolution of the SXS will enable dynamical studies of the X-ray emitting plasma. We also discuss the possibility of identifying an accreting, near-Chandrasekhar-mass white dwarf by measuring the gravitational redshift of the 6.4 keV line., Comment: 25 pages, 20 figures, ASTRO-H White Paper

Published
2014

29. ASTRO-H White Paper - Older Supernova Remnants and Pulsar Wind Nebulae

Author

Long, K. S., Bamba, A., Aharonian, F., Foster, A., Funk, S., Hiraga, J., Hughes, J., Ishida, M., Katsuda, S., Matsumoto, H., Mori, K., Nakajima, H., Nakamori, T., Ozaki, M., Safi-Harb, S., Sawada, M., Tamagawa, T., Tamura, K., Tanaka, T., Tsunemi, H., Uchida, H., Uchiyama, Y., and Yamauchi, S.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Most supernova remnants (SNRs) are old, in the sense that their structure has been profoundly modified by their interaction with the surrounding interstellar medium (ISM). Old SNRs are very heterogenous in terms of their appearance, reflecting differences in their evolutionary state, the environments in which SNe explode and in the explosion products. Some old SNRs are seen primarily as a result of a strong shock wave interacting with the ISM. Others, the so-called mixed-morphology SNRs, show central concentrations of emission, which may still show evidence of emission from the ejecta. Yet others, the pulsar wind nebulae (PWNe), are seen primarily as a result of emission powered by a pulsar; these SNRs often lack the detectable thermal emission from the primary shock. The underlying goal in all studies of old SNRs is to understand these differences, in terms of the SNe that created them, the nature of the ISM into which they are expanding, and the fundamental physical processes that govern their evolution. Here we identify three areas of study where ASTRO-H can make important contributions. These are constraining abundances and physical processes in mature limb-brightened SNRs, understanding the puzzling nature of mixed-morphology SNRs, and exploring the nature of PWNe. The Soft X-ray Spectrometer (SXS) on-board ASTRO-H will, as a result of its high spectral resolution, be the primary tool for addressing problems associated with old SNRs, supported by hard X-ray observations with the Hard X-ray Imager (HXI) to obtain broad band X-ray coverage., Comment: 25 pages, 17 figures, ASTRO-H White Paper

Published
2014

30. ASTRO-H White Paper - Young Supernova Remnants

Author

Hughes, J. P., Safi-Harb, S., Bamba, A., Katsuda, S., Leutenegger, M., Long, K. S., Maeda, Y., Mori, K., Nakajima, H., Sawada, M., Tanaka, T., Uchida, H., Yamaguchi, H., Aharonian, F., Funk, S., Hiraga, J., Ishida, M., Koyama, K., Matsumoto, H., Nobukawa, M., Ozaki, M., Tamagawa, T., Tsunemi, H., Tomida, H., Uchiyama, Y., and Uno, S.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Thanks to the unprecedented spectral resolution and sensitivity of the Soft X-ray Spectrometer (SXS) to soft thermal X-ray emission, ASTRO-H will open a new discovery window for understanding young, ejecta-dominated, supernova remnants (SNRs). In particular we study how ASTRO-H observations will address, comprehensively, three key topics in SNR research: (1) using abundance measurements to unveil SNR progenitors, (2) using spatial and velocity distribution of the ejecta to understand supernova explosion mechanisms, (3) revealing the link between the thermal plasma state of SNRs and the efficiency of their particle acceleration., Comment: 38 pages, 19 figures, ASTRO-H White Paper

Published
2014

31. Collisional history of Ryugu’s parent body from bright surface boulders

Author

Tatsumi, E., Sugimoto, C., Riu, L., Sugita, S., Nakamura, T., Hiroi, T., Morota, T., Popescu, M., Michikami, T., Kitazato, K., Matsuoka, M., Kameda, S., Honda, R., Yamada, M., Sakatani, N., Kouyama, T., Yokota, Y., Honda, C., Suzuki, H., Cho, Y., Ogawa, K., Hayakawa, M., Sawada, H., Yoshioka, K., Pilorget, C., Ishida, M., Domingue, D., Hirata, N., Sasaki, S., de León, J., Barucci, M. A., Michel, P., Suemitsu, M., Saiki, T., Tanaka, S., Terui, F., Nakazawa, S., Kikuchi, S., Yamaguchi, T., Ogawa, N., Ono, G., Mimasu, Y., Yoshikawa, K., Takahashi, T., Takei, Y., Fujii, A., Yamamoto, Y., Okada, T., Hirose, C., Hosoda, S., Mori, O., Shimada, T., Soldini, S., Tsukizaki, R., Mizuno, T., Iwata, T., Yano, H., Ozaki, M., Abe, M., Ohtake, M., Namiki, N., Tachibana, S., Arakawa, M., Ikeda, H., Ishiguro, M., Wada, K., Yabuta, H., Takeuchi, H., Shimaki, Y., Shirai, K., Hirata, N., Iijima, Y., Tsuda, Y., Watanabe, S., and Yoshikawa, M.

Published
2021
Full Text
View/download PDF

32. Modeling Dipolar Post-Shock Accretion Columns for Various Specific Accretion Rate Intermediate Polars

Author

Hayashi, T. and Ishida, M.

Subjects
Astrophysics - Solar and Stellar Astrophysics
Abstract

We model the post-shock accretion column (PSAC) for intermediate polars (IPs), with parameterizing specific accretion rate between 0.0001 and 100 g cm-2 s-1 and metal abundance between 0.1 and 2 times of solar abundance, and taking into account the gravitational potential and non-equipartition between ions, electrons and ionization degree. We assume the cylinder and dipole as geometry of the PSAC. The PSAC becomes higher against the white dwarf (WD) radius for lower specific accretion rate and more massive WD, and may be comparable to the WD radius. The consideration of the dipolar geometry significantly reduces the density and temperature over the whole PSAC comparing with the cylindrical case when the specific accretion rate is lower than a threshold which the PSAC height reachs 0.2 RWD with and is decreased by the more massive white dwarf. We calculate the spectra of the cylindrical and dipolar PSACs with the wide range of the specific accretion rate. Although the spectra soften as the specific accretion rate decreases for the both geometrical assumptions under the specific accretion rate threshold, the softening is more speedy for the dipolar PSAC. The fact means that the both geometrical assumptions lead the different WD masses for each other when their spectra are applied to the IPs hosting the low accretion or a massive WD. Although the ionization non-equilibrium are also involved for the spectral calculation, the effects are trivial because the radiation from ionization non-equilibrium plasma is a few percent of the whole at most., Comment: submitted to MNRAS, 11 pages, 10 figures

Published
2013

33. Observation of Longitudinal Spin Seebeck Effect with Various Transition Metal Films

Author

Ishida, M., Kirihara, A., Someya, H., Uchida, K., Kohmoto, S., Saitoh, E., and Murakami, T.

Subjects
Condensed Matter - Materials Science, Condensed Matter - Mesoscale and Nanoscale Physics
Abstract

We evaluated the thermoelectric properties of longitudinal spin Seebeck devices by using ten different transition metals (TMs). Both the intensity and sign of spin Seebeck coefficients were noticeably dependent on the degree of the inverse spin Hall effect and the resistivity of each TM film. Spin dependent behaviors were also observed under ferromagnetic resonance. These results indicate that the output of the spin Seebeck devices originates in the spin current., Comment: 14 pages, 4 figures

Published
2013

35. Searching for Stoponium along with the Higgs boson

Author

Barger, V., Ishida, M., and Keung, W. -Y.

Subjects
High Energy Physics - Phenomenology, High Energy Physics - Experiment
Abstract

Stoponium, a bound state of top squark and its antiparticle in a supersymmetric model, may be found in the ongoing Higgs searches at the LHC. Its WW and ZZ detection ratios relative to the Standard Model Higgs boson can be more than unity from WW* threshold to the two Higgs threshold. The gamma gamma channel is equally promising. Some regions of the stoponium mass below 150 GeV are already being probed by the ATLAS and CMS experiments., Comment: 10 pages 5 figures

Published
2011
Full Text
View/download PDF

36. X-ray observation of AM Herculis in a very low state with Suzaku

Author

Terada, Y., Ishida, M., Bamba, A., Mukai, K., Hayashi, T., and Harayama, A.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

The X-ray observation of AM Her in a very low state was performed with {\it Suzaku} in October 2008. One flare event with a time scale of $\sim$ 3700 sec was detected at the X-ray luminosity of $6.0 \times 10^{29} {\rm ~erg ~sec}^{-1}$ in the 0.5 -- 10 keV band assuming at a distance of 91 pc. The X-ray spectrum is represented by a thermal plasma emission model with a temperature of $8.67_{-1.14}^{+1.31}$ keV. During the quiescence out of the flare interval, {\it Suzaku} also detected significant X-rays at a luminosity of $1.7 \times 10^{29} {\rm ~erg ~sec}^{-1}$ in the 0.5 -- 10 keV band, showing a clear spin modulation at a period of 0.1289273(2) days at BJD 2454771.581. The X-ray spectra in the quiescence were represented by a MEKAL + Power Law (PL) model or a single CEMEKL model, which are also supported by phase-resolved analyses. A correlation between the temperature and the volume emission measure was found together with historical X-ray measurements of AM Her in various states. In order to account for a possible non-thermal emission from AM Her, particle acceleration mechanisms in the AM Her system are also discussed, including a new proposal of a shock acceleration process on the top of the accretion column., Comment: 16 pages, 9 figures, 4 tables, Accepted for publication in Astrophysical Journal

Published
2010
Full Text
View/download PDF

37. Suzaku X-Ray Imaging and Spectroscopy of Cassiopeia A

Author

Maeda, Y., Uchiyama, Y., Bamba, A., Kosugi, H., Tsunemi, H., Helder, E. A., Vink, J., Kodaka, N., Terada, Y., Fukazawa, Y., Hiraga, J., Hughes, J. P., Kokubun, M., Kouzu, T., Matsumoto, H., Miyata, E., Nakamura, R., Okada, S., Someya, K., Tamagawa, T., Tamura, K., Totsuka, K., Tsuboi, Y., Ezoe, Y., Holt, S. S., Ishida, M., Kamae, T., Petre, R., and Takahashi, T.

Subjects
Astrophysics - High Energy Astrophysical Phenomena
Abstract

Suzaku X-ray observations of a young supernova remnant, Cassiopeia A, were carried out. K-shell transition lines from highly ionized ions of various elements were detected, including Chromium (Cr-Kalpha at 5.61 keV). The X-ray continuum spectra were modeled in the 3.4--40 keV band, summed over the entire remnant, and were fitted with a simplest combination of the thermal bremsstrahlung and the non-thermal cut-off power-law models. The spectral fits with this assumption indicate that the continuum emission is likely to be dominated by the non-thermal emission with a cut-off energy at > 1 keV. The thermal-to-nonthermal fraction of the continuum flux in the 4-10 keV band is best estimated as ~0.1. Non-thermal-dominated continuum images in the 4--14 keV band were made. The peak of the non-thermal X-rays appears at the western part. The peak position of the TeV gamma-rays measured with HEGRA and MAGIC is also shifted at the western part with the 1-sigma confidence. Since the location of the X-ray continuum emission was known to be presumably identified with the reverse shock region, the possible keV-TeV correlations give a hint that the accelerated multi-TeV hadrons in Cassiopeia A are dominated by heavy elements in the reverse shock region., Comment: Publ. Astron. Soc. Japan 61, pp.1217-1228 (2009)

Published
2009
Full Text
View/download PDF

38. Broad-band properties of the hard X-ray cataclysmic variables IGR J00234+6141 and 1RXS J213344.1+510725

Author

Anzolin, G., de Martino, D., Falanga, M., Mukai, K., Bonnet-Bidaud, J. -M., Mouchet, M., Terada, Y., and Ishida, M.

Subjects
Astrophysics - Solar and Stellar Astrophysics, Astrophysics - High Energy Astrophysical Phenomena
Abstract

A significant number of cataclysmic variables were detected as hard X-ray sources in the INTEGRAL survey, most of them of the magnetic intermediate polar type. We present a detailed X-ray broad-band study of two new sources, IGR J00234+6141 and 1RXS J213344.1+510725, that allow us to classify them as secure members of the intermediate polar class. Timing and spectral analysis of IGR J00234+6141 are based on a XMM-Newton observation and INTEGRAL publicly available data. For 1RXS J213344.1+510725 we use XMM-Newton and Suzaku observations at different epochs, as well as INTEGRAL publicly available data. We determine a spin period of 561.64 +/- 0.56 s for the white dwarf in IGR J00234+6141. The X-ray pulses are observed up to about 2 keV. From XMM-Newton and Suzaku observations of 1RXS J213344.1+510725, we find a rotational period of 570.862 +/- 0.034 s. The observations span three epochs where the pulsation is observed to change at different energies both in amplitude and shape. In both objects, the spectral analysis spanned over a wide energy range, from 0.3 to 100 keV, shows the presence of multiple emission components absorbed by dense material. The X-ray spectrum of IGR J00234+6141 is consistent with a multi-temperature plasma with a maximum temperature of about 50 keV. In 1RXS J213344.1+510725, multiple optically thin components are inferred, as well as an optically thick (blackbody) soft X-ray emission with a temperature of about 100 eV. This latter adds 1RXS J213344.1+510725 to the growing group of soft X-ray intermediate polars. (abridged), Comment: 12 pages, 8 figures, 5 tables. Accepted for publication in A&A

Published
2009
Full Text
View/download PDF

39. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission

Author

Feigin, V, Owolabi, M, Abd-Allah, F, Akinyemi, R, Bhattacharjee, N, Brainin, M, Cao, J, Caso, V, Dalton, B, Davis, A, Dempsey, R, Duprey, J, Feng, W, Ford, G, Gall, S, Gandhi, D, Good, D, Hachinski, V, Hacke, W, Hankey, G, Ishida, M, Johnson, W, Kim, J, Lavados, P, Lindsay, P, Mahal, A, Martins, S, Murray, C, Nguyen, T, Norrving, B, Olaiya, M, Olalusi, O, Pandian, J, Phan, H, Platz, T, Ranta, A, Rehman, S, Roth, G, Sebastian, I, Smith, A, Suwanwela, N, Sylaja, P, Thapa, R, Thrift, A, Uvere, E, Vollset, S, Yavagal, D, Yaria, J, Abera, S, Ibrahim, N, Liu, L, Ovbiagele, B, Piradov, M, Abanto, C, Addissie, A, Adeleye, A, Adilbekov, Y, Adilbekova, B, Adoukonou, T, Aguiar de Sousa, D, Akhmetzhanova, Z, Akpalu, A, El Alaoui-Faris, M, Ameriso, S, Andonova, S, Arsovska, A, Awoniyi, F, Bakhiet, M, Barboza, M, Basri, H, Bath, P, Bereczki, D, Beretta, S, Berkowitz, A, Bernhardt, J, Berzina, G, Bhavsar, B, Bisharyan, M, Bohara, M, Bovet, P, Budincevic, H, Cadilhac, D, Cerimagic, D, Charway-Felli, A, Chen, C, Chin, J, Christensen, H, Chwojnicki, K, Conforto, A, Correia, M, Mora Cuervo, D, Czlonkowska, A, D'Amelio, M, Danielyan, K, Davis, S, Demarin, V, Demchuk, A, Dichgans, M, Dokova, K, Donnan, G, Duran, J, Ekeng, G, Elkind, M, Endres, M, Fischer, U, Flomin, Y, Gankpe, F, Gavidia, M, Gaye Saavedra, A, Gebreyohanns, M, George, M, Gierlotka, M, Giroud, M, Gnedovskaya, E, Goncalves, I, Gongora-Rivera, F, Gunaratne, P, Hamadeh, R, Hamzat, T, Heldner, M, Ibrahim, E, Ihle-Hansen, H, Jee, S, Jiann-Shing, J, Johnston, S, Jovanovic, D, Jurjans, K, Kalani, R, Kalkonde, Y, Kamenova, S, Karaszewski, B, Kelly, P, Kiechl, S, Kondybayeva, A, Korv, J, Kozera, G, Kravchenko, M, Krespi, Y, Krishnamurthi, R, Kruja, J, Kutluk, K, Langhorne, P, Law, Z, Lebedynets, D, Lee, T, Leung, T, Liebeskind, D, Lopez-Jaramillo, P, Lotufo, P, Machline-Carrion, M, Maia, L, Malojcic, B, Markus, H, Marquez-Romero, J, Medina, M, Medukhanova, S, Mehndiratta, M, Miglane, E, Mihejeva, I, Mikulik, R, Mirrakhimov, E, Mohl, S, Munakomi, S, Murphy, S, Musa, K, Nasreldein, A, Nogueira, R, Nolte, C, Noubiap, J, Novarro-Escudero, N, Ocampo, C, O'Donnell, M, Ogun, Y, Ogunniyi, A, Oraby, M, Orken, D, Ozdemir, A, Ozturk, S, Paccot, M, Pereira, T, Peeters, A, Potpara, T, Proios, H, Rathore, F, Sacco, R, Sahathevan, R, Sandset, E, Renato Santos, I, Saposnik, G, Sarfo, F, Sargento-Freitas, J, Sharma, M, Shaw, L, Sheth, K, Shin, Y, Shobhana, A, Silva, S, Tedim Cruz, V, Thakur, K, Thapa, L, Toni, D, Topcuoglu, M, Torales, J, Towfighi, A, Truelsen, T, Tsiskaridze, A, Tulloch-Reid, M, Useche, J, Vanacker, P, Vassilopoulou, S, Vukorepa, G, Vuletic, V, Wahab, K, Wang, W, Wijeratne, T, Wojtyniak, B, Wolfe, C, Yacouba, M, Yang, J, Yifru, Y, Yock-Corrales, A, Yonemoto, N, Yperzeele, L, Zagozdzon, P, Feigin V. L., Owolabi M. O., Abd-Allah F., Akinyemi R. O., Bhattacharjee N. V., Brainin M., Cao J., Caso V., Dalton B., Davis A., Dempsey R., Duprey J., Feng W., Ford G. A., Gall S., Gandhi D., Good D. C., Hachinski V., Hacke W., Hankey G. J., Ishida M., Johnson W., Kim J., Lavados P., Lindsay P., Mahal A., Martins S., Murray C., Nguyen T. P., Norrving B., Olaiya M. T., Olalusi O. V., Pandian J., Phan H., Platz T., Ranta A., Rehman S., Roth G., Sebastian I. A., Smith A. E., Suwanwela N. C., Sylaja P. N., Thapa R., Thrift A. G., Uvere E., Vollset S. E., Yavagal D., Yaria J., Abera S. F., Akinyemi R., Dempsey R. J., Ibrahim N. M., Liu L., Ovbiagele B., Piradov M., Suwanwela N., Abanto C., Addissie A., Adeleye A. O., Adilbekov Y., Adilbekova B., Adoukonou T. A., Aguiar de Sousa D., Akhmetzhanova Z., Akpalu A., El Alaoui-Faris M., Ameriso S. F., Andonova S., Arsovska A., Awoniyi F. E., Bakhiet M., Barboza M. A., Basri H., Bath P. M., Bereczki D., Beretta S., Berkowitz A. L., Bernhardt J., Berzina G., Bhavsar B., Bisharyan M. S., Bohara M., Bovet P., Budincevic H., Cadilhac D. A., Cerimagic D., Charway-Felli A., Chen C., Chin J. H., Christensen H., Chwojnicki K., Conforto A. B., Correia M., Mora Cuervo D. L., Czlonkowska A., D'Amelio M., Danielyan K. E., Davis S., Demarin V., Demchuk A. M., Dichgans M., Dokova K., Donnan G., Duran J. C., Ekeng G., Elkind M. S., Endres M., Fischer U., Flomin Y., Gankpe F., Gavidia M., Gaye Saavedra A., Gebreyohanns M., George M., Gierlotka M., Giroud M., Gnedovskaya E. V., Goncalves I. P., Gongora-Rivera F., Gunaratne P. S., Hamadeh R. R., Hamzat T. -H. K., Heldner M. R., Ibrahim E., Ihle-Hansen H., Jee S., Jiann-Shing J., Johnston S. C., Jovanovic D., Jurjans K., Kalani R., Kalkonde Y., Kamenova S., Karaszewski B., Kelly P., Kiechl S., Kondybayeva A., Korv J., Kozera G., Kravchenko M., Krespi Y., Krishnamurthi R., Kruja J., Kutluk K., Langhorne P., Law Z. K., Lebedynets D., Lee T. -H., Leung T. W., Liebeskind D. S., Lopez-Jaramillo P., Lotufo P. A., Machline-Carrion M. J., Maia L. F., Malojcic B., Markus H. S., Marquez-Romero J. M., Medina M. T., Medukhanova S., Mehndiratta M. M., Miglane E., Mihejeva I., Mikulik R., Mirrakhimov E., Mohl S., Munakomi S., Murphy S., Musa K. I., Nasreldein A., Nogueira R. G., Nolte C. H., Noubiap J. J., Novarro-Escudero N., Ocampo C., O'Donnell M., Ogun Y., Ogunniyi A., Oraby M. I., Orken D. N., Ozdemir A. O., Ozturk S., Paccot M., Pereira T., Peeters A., Potpara T., Proios H., Rathore F. A., Sacco R. L., Sahathevan R., Sandset E. S., Renato Santos I., Saposnik G., Sarfo F. S., Sargento-Freitas J., Sharma M., Shaw L., Sheth K. N., Shin Y. -I., Shobhana A., Silva S. N., Tedim Cruz V., Thakur K., Thapa L. J., Toni D., Topcuoglu M. A., Torales J., Towfighi A., Truelsen T., Tsiskaridze A., Tulloch-Reid M., Useche J. N., Vanacker P., Vassilopoulou S., Vukorepa G., Vuletic V., Wahab K. W., Wang W., Wijeratne T., Wojtyniak B., Wolfe C., Yacouba M. N., Yang J., Yifru Y. M., Yock-Corrales A., Yonemoto N., Yperzeele L., Zagozdzon P., Feigin, V, Owolabi, M, Abd-Allah, F, Akinyemi, R, Bhattacharjee, N, Brainin, M, Cao, J, Caso, V, Dalton, B, Davis, A, Dempsey, R, Duprey, J, Feng, W, Ford, G, Gall, S, Gandhi, D, Good, D, Hachinski, V, Hacke, W, Hankey, G, Ishida, M, Johnson, W, Kim, J, Lavados, P, Lindsay, P, Mahal, A, Martins, S, Murray, C, Nguyen, T, Norrving, B, Olaiya, M, Olalusi, O, Pandian, J, Phan, H, Platz, T, Ranta, A, Rehman, S, Roth, G, Sebastian, I, Smith, A, Suwanwela, N, Sylaja, P, Thapa, R, Thrift, A, Uvere, E, Vollset, S, Yavagal, D, Yaria, J, Abera, S, Ibrahim, N, Liu, L, Ovbiagele, B, Piradov, M, Abanto, C, Addissie, A, Adeleye, A, Adilbekov, Y, Adilbekova, B, Adoukonou, T, Aguiar de Sousa, D, Akhmetzhanova, Z, Akpalu, A, El Alaoui-Faris, M, Ameriso, S, Andonova, S, Arsovska, A, Awoniyi, F, Bakhiet, M, Barboza, M, Basri, H, Bath, P, Bereczki, D, Beretta, S, Berkowitz, A, Bernhardt, J, Berzina, G, Bhavsar, B, Bisharyan, M, Bohara, M, Bovet, P, Budincevic, H, Cadilhac, D, Cerimagic, D, Charway-Felli, A, Chen, C, Chin, J, Christensen, H, Chwojnicki, K, Conforto, A, Correia, M, Mora Cuervo, D, Czlonkowska, A, D'Amelio, M, Danielyan, K, Davis, S, Demarin, V, Demchuk, A, Dichgans, M, Dokova, K, Donnan, G, Duran, J, Ekeng, G, Elkind, M, Endres, M, Fischer, U, Flomin, Y, Gankpe, F, Gavidia, M, Gaye Saavedra, A, Gebreyohanns, M, George, M, Gierlotka, M, Giroud, M, Gnedovskaya, E, Goncalves, I, Gongora-Rivera, F, Gunaratne, P, Hamadeh, R, Hamzat, T, Heldner, M, Ibrahim, E, Ihle-Hansen, H, Jee, S, Jiann-Shing, J, Johnston, S, Jovanovic, D, Jurjans, K, Kalani, R, Kalkonde, Y, Kamenova, S, Karaszewski, B, Kelly, P, Kiechl, S, Kondybayeva, A, Korv, J, Kozera, G, Kravchenko, M, Krespi, Y, Krishnamurthi, R, Kruja, J, Kutluk, K, Langhorne, P, Law, Z, Lebedynets, D, Lee, T, Leung, T, Liebeskind, D, Lopez-Jaramillo, P, Lotufo, P, Machline-Carrion, M, Maia, L, Malojcic, B, Markus, H, Marquez-Romero, J, Medina, M, Medukhanova, S, Mehndiratta, M, Miglane, E, Mihejeva, I, Mikulik, R, Mirrakhimov, E, Mohl, S, Munakomi, S, Murphy, S, Musa, K, Nasreldein, A, Nogueira, R, Nolte, C, Noubiap, J, Novarro-Escudero, N, Ocampo, C, O'Donnell, M, Ogun, Y, Ogunniyi, A, Oraby, M, Orken, D, Ozdemir, A, Ozturk, S, Paccot, M, Pereira, T, Peeters, A, Potpara, T, Proios, H, Rathore, F, Sacco, R, Sahathevan, R, Sandset, E, Renato Santos, I, Saposnik, G, Sarfo, F, Sargento-Freitas, J, Sharma, M, Shaw, L, Sheth, K, Shin, Y, Shobhana, A, Silva, S, Tedim Cruz, V, Thakur, K, Thapa, L, Toni, D, Topcuoglu, M, Torales, J, Towfighi, A, Truelsen, T, Tsiskaridze, A, Tulloch-Reid, M, Useche, J, Vanacker, P, Vassilopoulou, S, Vukorepa, G, Vuletic, V, Wahab, K, Wang, W, Wijeratne, T, Wojtyniak, B, Wolfe, C, Yacouba, M, Yang, J, Yifru, Y, Yock-Corrales, A, Yonemoto, N, Yperzeele, L, Zagozdzon, P, Feigin V. L., Owolabi M. O., Abd-Allah F., Akinyemi R. O., Bhattacharjee N. V., Brainin M., Cao J., Caso V., Dalton B., Davis A., Dempsey R., Duprey J., Feng W., Ford G. A., Gall S., Gandhi D., Good D. C., Hachinski V., Hacke W., Hankey G. J., Ishida M., Johnson W., Kim J., Lavados P., Lindsay P., Mahal A., Martins S., Murray C., Nguyen T. P., Norrving B., Olaiya M. T., Olalusi O. V., Pandian J., Phan H., Platz T., Ranta A., Rehman S., Roth G., Sebastian I. A., Smith A. E., Suwanwela N. C., Sylaja P. N., Thapa R., Thrift A. G., Uvere E., Vollset S. E., Yavagal D., Yaria J., Abera S. F., Akinyemi R., Dempsey R. J., Ibrahim N. M., Liu L., Ovbiagele B., Piradov M., Suwanwela N., Abanto C., Addissie A., Adeleye A. O., Adilbekov Y., Adilbekova B., Adoukonou T. A., Aguiar de Sousa D., Akhmetzhanova Z., Akpalu A., El Alaoui-Faris M., Ameriso S. F., Andonova S., Arsovska A., Awoniyi F. E., Bakhiet M., Barboza M. A., Basri H., Bath P. M., Bereczki D., Beretta S., Berkowitz A. L., Bernhardt J., Berzina G., Bhavsar B., Bisharyan M. S., Bohara M., Bovet P., Budincevic H., Cadilhac D. A., Cerimagic D., Charway-Felli A., Chen C., Chin J. H., Christensen H., Chwojnicki K., Conforto A. B., Correia M., Mora Cuervo D. L., Czlonkowska A., D'Amelio M., Danielyan K. E., Davis S., Demarin V., Demchuk A. M., Dichgans M., Dokova K., Donnan G., Duran J. C., Ekeng G., Elkind M. S., Endres M., Fischer U., Flomin Y., Gankpe F., Gavidia M., Gaye Saavedra A., Gebreyohanns M., George M., Gierlotka M., Giroud M., Gnedovskaya E. V., Goncalves I. P., Gongora-Rivera F., Gunaratne P. S., Hamadeh R. R., Hamzat T. -H. K., Heldner M. R., Ibrahim E., Ihle-Hansen H., Jee S., Jiann-Shing J., Johnston S. C., Jovanovic D., Jurjans K., Kalani R., Kalkonde Y., Kamenova S., Karaszewski B., Kelly P., Kiechl S., Kondybayeva A., Korv J., Kozera G., Kravchenko M., Krespi Y., Krishnamurthi R., Kruja J., Kutluk K., Langhorne P., Law Z. K., Lebedynets D., Lee T. -H., Leung T. W., Liebeskind D. S., Lopez-Jaramillo P., Lotufo P. A., Machline-Carrion M. J., Maia L. F., Malojcic B., Markus H. S., Marquez-Romero J. M., Medina M. T., Medukhanova S., Mehndiratta M. M., Miglane E., Mihejeva I., Mikulik R., Mirrakhimov E., Mohl S., Munakomi S., Murphy S., Musa K. I., Nasreldein A., Nogueira R. G., Nolte C. H., Noubiap J. J., Novarro-Escudero N., Ocampo C., O'Donnell M., Ogun Y., Ogunniyi A., Oraby M. I., Orken D. N., Ozdemir A. O., Ozturk S., Paccot M., Pereira T., Peeters A., Potpara T., Proios H., Rathore F. A., Sacco R. L., Sahathevan R., Sandset E. S., Renato Santos I., Saposnik G., Sarfo F. S., Sargento-Freitas J., Sharma M., Shaw L., Sheth K. N., Shin Y. -I., Shobhana A., Silva S. N., Tedim Cruz V., Thakur K., Thapa L. J., Toni D., Topcuoglu M. A., Torales J., Towfighi A., Truelsen T., Tsiskaridze A., Tulloch-Reid M., Useche J. N., Vanacker P., Vassilopoulou S., Vukorepa G., Vuletic V., Wahab K. W., Wang W., Wijeratne T., Wojtyniak B., Wolfe C., Yacouba M. N., Yang J., Yifru Y. M., Yock-Corrales A., Yonemoto N., Yperzeele L., and Zagozdzon P.

Published
2023

40. The NeXT Mission

Author

Takahashi, T., Kelley, R., Mitsuda, K., Kunieda, H., Petre, R., White, N., Dotani, T., Fujimoto, R., Fukazawa, Y., Hayashida, K., Ishida, M., Ishisaki, Y., Kokubun, M., Makishima, K., Koyama, K., Madejski, G. M., Mori, K., Mushotzky, R., Nakazawa, K., Ogasaka, Y., Ohashi, T., Ozaki, M., Tajima, H., Tashiro, M., Terada, Y., Tsunemi, H., Tsuru, T. G., Ueda, Y., Yamasaki, N., Watanabe, S., and team, the NeXT

Subjects
Astrophysics
Abstract

The NeXT (New exploration X-ray Telescope), the new Japanese X-ray Astronomy Satellite following Suzaku, is an international X-ray mission which is currently planed for launch in 2013. NeXT is a combination of wide band X-ray spectroscopy (3 - 80 keV) provided by multi-layer coating, focusing hard X-ray mirrors and hard X-ray imaging detectors, and high energy-resolution soft X-ray spectroscopy (0.3 - 10 keV) provided by thin-foil X-ray optics and a micro-calorimeter array. The mission will also carry an X-ray CCD camera as a focal plane detector for a soft X-ray telescope and a non-focusing soft gamma-ray detector. With these instruments, NeXT covers very wide energy range from 0.3 keV to 600 keV. The micro-calorimeter system will be developed by international collaboration lead by ISAS/JAXA and NASA. The simultaneous broad bandpass, coupled with high spectral resolution of Delta E ~ 7 eV by the micro-calorimeter will enable a wide variety of important science themes to be pursued., Comment: 14 pages, 10 figures, Proceedings of the SPIE meeting, "Space Telescopes and Instrumentation II: Ultraviolet to Gamma Ray 2008", Marseille (2008)

Published
2008
Full Text
View/download PDF

42. DIOS: the Diffuse Intergalactic Oxygen Surveyor

Author

Ohashi, T., Ishida, M., Sasaki, S., Ishisaki, Y., Mitsuda, K., Yamasaki, N. Y., Fujimoto, R., Takei, Y., Tawara, Y., Furuzawa, A., Suto, Y., Yoshikawa, K., Kawahara, H., Kawai, N., Tsuru, T. G., Matsushita, K., and Kitayama, T.

Subjects
Astrophysics
Abstract

We present our proposal for a small X-ray mission DIOS (Diffuse Intergalactic Oxygen Surveyor), consisting of a 4-stage X-ray telescope and an array of TES microcalorimeters, cooled with mechanical coolers, with a total weight of about 400 kg. The mission will perform survey observations of warm-hot intergalactic medium using OVII and OVIII emission lines, with the energy coverage up to 1.5 keV. The wide field of view of about 50' diameter, superior energy resolution close to 2 eV FWHM, and very low background will together enable us a wide range of science for diffuse X-ray sources. We briefly describe the design of the satellite, performance of the subsystems and the expected results., Comment: 9 pages, 11 figures, a proceedings of SPIE "Astronomical Telescopes and Instrumentation" 2006

Published
2006
Full Text
View/download PDF

43. XMM-Newton Observation of IC 310 in the Outer Region of the Perseus Cluster of Galaxies

Author

Sato, K., Furusho, T., Yamasaki, N. Y., Ishida, M., Matsushita, K., and Ohashi, T.

Subjects
Astrophysics
Abstract

We present results from an XMM-Newton observation of the head-tail radio galaxy IC 310 located in the southwest region of the Perseus cluster. The spectrum is well-fitted by an absorbed power-law model with a photon index of $2.50 \pm 0.02$ with no significant absorption excess. The X-ray image shows a point-like emission at IC 310 without any signs of a structure correlated with the radio halo tail. The temperature of the intracluster medium surrounding IC 310 declines as a function of distance from the cluster center, from $ kT \sim 6$ keV in the northeast corner of the field of view to about 3 keV in the southwest region. Although we do not find any sharp edges in the surface brightness profile, a brightness excess over a smooth $\beta$ model by about 20% is seen. The temperature also rises by about 10% in the same region. This indicates that the IC 310 region is a subcluster probably infalling into the Perseus cluster, and the gas in front of IC 310 towards the Perseus cluster is likely to be compressed by the large-scale motion, which supports the view that the IC 310 system is undergoing a merger., Comment: 7 pages, 8 figures (including color), accepted for publication in PASJ

Published
2005
Full Text
View/download PDF

44. The role of imprinted genes in human fetal growth

Author

Ishida, M.

Subjects
576.5
Abstract

Identifying the genes important for fetal growth will help to understand common, serious complications of pregnancy such as intrauterine growth restriction (IUGR). Of particular interest are imprinted genes, which show monoallelic, parent-of-origin specific expression. Genes that are paternally derived tend to enhance fetal growth whereas maternally expressed genes suppress growth. A significant correlation between lower birth weight and increased expression of maternally expressed, pleckstrin homology-like domain, family A, member 2 (PHLDA2) in term placenta, without loss of imprinting, had been reported previously. We have identified a novel copy number variant (CNV1) in the PHLDA2 promoter which reduced the promoter efficiency in a luciferase reporter gene assay. Meta-analysis of CNV1 genotype data obtained from three independent white European normal birth cohorts (total n = 9,433) showed that maternal inheritance of CNV1 resulted in a 93 g increase in birth weight (P = 0.01). Moreover, when the mother was homozygous for CNV1, the influence on birth weight was 155 g (P = 0.04), a similar magnitude to the reduction caused by maternal smoking. The expression levels of paternally expressed gene 3 (PEG3), delta-like 1 homolog (DLK1) and maternally expressed gene 3 (MEG3) measured by real-time PCR in >110 normal term placentas from a white European cohort did not show correlation with fetal birth size measurements, except for a trend of positive association observed for DLK1 expression and birth weight (P = 0.072). Paternal inheritance of the type 1 diabetes (T1D) protective G allele of rs941576 SNP located in the DLK1-MEG3 locus was shown to be associated with a 132 g (P = 0.011) and 0.5 cm (P = 0.011) reduction in birth weight and head circumference respectively. This newly described PHLDA2 promoter CNV and rs941576 SNP, alongside their expressions, may provide useful genetic biomarkers/indicators for predicting birth size.

Published
2012

46. Locating the Warm-Hot Intergalactic Medium in the Simulated Local Universe

Author

Yoshikawa, K., Dolag, K., Suto, Y., Sasaki, S., Yamasaki, N. Y., Ohashi, T., Mitsuda, K., Tawara, Y., Fujimoto, R., Furusho, T., Furuzawa, A., Ishida, M., Ishisaki, Y., and Takei, Y.

Subjects
Astrophysics
Abstract

We present an analysis of mock spectral observation of warm-hot intergalactic medium (WHIM) using a constrained simulation of the local universe. The simulated map of oxygen emission lines from local WHIM reproduces well the observed structures traced by galaxies in the real local universe. We further attempt to perform mock observations of outer parts of simulated Coma cluster and A3627 adopting the expected performance of DIOS (Diffuse Intergalactic Oxygen Surveyor), which is proposed as a dedicated soft X-ray mission to search for cosmic missing baryons. We find that WHIMs surrounding nearby clusters are detectable with a typical exposure time of a day, and thus constitute realistic and promising targets for DIOS. We also find that an X-ray emitting clump in front of Coma cluster, recently reported in the XMM-Newton observation, has a counterpart in the simulated local universe, and its observed spectrum can be well reproduced in the simulated local universe if the gas temperature is set to the observationally estimated value., Comment: 25 pages, 3 tables, 16 figures. Accepted for publication in PASJ. High resolution PS/PDF files are available at http://www-utap.phys.s.u-tokyo.ac.jp/~kohji/research/x-ray/index.html

Published
2004
Full Text
View/download PDF

47. Future Japanese missions for the study of warm-hot intergalactic medium

Author

Ohashi, T., Ishida, M., Sasaki, S., Ishisaki, Y., Mitsuda, K., Yamasaki, N. Y., Fujimoto, R., Furusho, T., Kunieda, H., Tawara, Y., Furuzawa, A., Suto, Y., and Yoshikawa, K.

Subjects
Astrophysics
Abstract

We present our proposal for a small X-ray mission DIOS (Diffuse Intergalactic Oxygen Surveyor) to perform survey observations of warm-hot intergalactic medium using OVII and OVIII emission lines. This will be proposed to a small satellite program planned by ISAS/JAXA in Japan for a launch in 2008. The instrument consists of an array of TES microcalorimeters with an energy resolution 2 eV, cooled by mechanical coolers. The X-ray telescope will employ 4-stage reflection mirrors with a focal length as short as 70 cm and an angular resolution 2'. In addition to DIOS, we briefly describe the NeXT (New X-ray Telescope) mission, which is a larger Japanese X-ray observatory to be launched in 2010 and plans to explore non-thermal processes in the universe., Comment: 6 pages, 9 figures. To appear in the proceedings of "Modelling the Intergalactic and Intracluster Media", Vulcano Island, October 1-4, 2003

Published
2004

49. X-Ray Beaming due to Resonance Scattering in the Accretion Column of Magnetic Cataclysmic Variables

Author

Terada, Yukikatsu., Ishida, M., Makishima, K., Imanari, T., Fujimoto, R., Matsuzaki, K., and Kaneda, H.

Subjects
Astrophysics
Abstract

Extremely strong ionized Fe emission lines, with the equivalent width reaching about 4000 eV, were discovered with ASCA from a few Galactic compact objects, including AX J2315-0592, RX J1802.1+1804 and AX J1842.8-0423. These objects are thought to be binary systems containing magnetized white dwarfs (WDs). A possible interpretation of the strong Fe-K line is the line-photon collimation in the WD accretion column, due to resonance scattering of line photons. The collimation occurs when the accretion column has a flat shape, and the effect is augmented by the vertical velocity gradient there, which reduces the resonant trapping of resonant photons along the magnetic field lines. This effect was quantitatively confirmed with Monte-Carlo simulations. Furthermore, with ASCA observations of the polar V834 Centauri, this collimation effect was clearly detected as a rotational modulation of the equivalent width of the Fe-K emission line. Extremely strong emission lines mentioned above can be explained by our interpretation consistently. Combing this effect with other X-ray information, the geometry and plasma parameters in the accretion column were determined., Comment: 16 pages, Postscript, 32 figures, and 4 tables; accepted for MNRAS (Monthly Notices of The Royal Astronomical Society) on July 24, 2001

Published
2001
Full Text
View/download PDF

50. Temperature Map of the Virgo Cluster of Galaxies Observed with ASCA

Author

Shibata, R., Matsushita, K., Yamasaki, N. Y., Ohashi, T., Ishida, M., Kikuchi, K., Boehringer, H., and Matsumoto, H.

Subjects
Astrophysics
Abstract

The temperature distribution of the intracluster medium (ICM) in the Virgo cluster of galaxies has been derived from extensive mapping observations with ASCA covering an area of 19 deg^2. In the spectral analysis, the inner region within a radius of ~60' from M87 is characterized by an ICM temperature of kT \~2.5 keV with little variation. On the other hand, the outer regions indicate significant variation of the temperature with an amplitude of about 1 keV. The temperature map was produced from the hardness ratio (H.R.) values with a resolution of about 5'. Besides the previously reported hot region with kT > 4 keV between M87 and M49, several hot regions with kT = 3-4 keV are detected in the cluster outskirts. The auto-correlation function for the H.R. variation shows that the temperature variation is correlated within a size of about 300 kpc, suggesting that gas blobs falling in the Virgo cluster have a typical size of groups of galaxies. A correlation with the velocity dispersion of member galaxies shows that only the north-west region indicates an unusually large beta_spec value of 2-4. The upper limit for extended non-thermal emission in the Virgo cluster is obtained to be L_X ~9 x 10^41 ergs/s in the 2 - 10 keV band. We discuss that these features consistently indicate that the Virgo cluster is in a relatively early stage of the cluster evolution., Comment: 37 pages, including 12 Postscript figures, accepted for publication in ApJ

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results